dfv890
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started May 15, 2020 (NCT04382053)
Timeline
Indications
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06097663 | Phase 2 | Feb 9, 2024 | Novartis |
| NCT06031844 | Phase 2 | Oct 16, 2023 | Novartis |
| NCT05552469 | Phase 1 | Feb 28, 2023 | Novartis |
| NCT04868968 | Phase 2 | Sep 20, 2021 | Novartis |
| NCT04886258 | Phase 2 | Sep 20, 2021 | Novartis |
| NCT04382053 | Phase 2 | May 15, 2020 | Novartis |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 6 | 6 | 2 | 2020 |
1 organizations
Page 1 / 1